Q2 FY2026 · ended Jun 30, 2026 · Revenue $5.00M, +408.6% YoY · Filed Aug 6, 2026
Surrozen, Inc./DE (SRZN) files with the SEC under industry code 2836, Biological Products, (No Diagnostic Substances). In Q2 of fiscal 2026, the quarter ended Jun 30, 2026, it reported revenue of $5.0 million and net income of $50.2 million. Free cash flow was -$7.4 million. As of Jun 30, 2026 it held $102.0 million in cash and investments and $6.3 million in total debt.
Company profile
- Industry
- Biological Products, (No Diagnostic Substances) (SIC 2836)
- Listed as
- SRZN (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- South San Francisco, CA
- SEC filer status
- Non-accelerated filer, Smaller reporting company
- SEC CIK
- 1824893
- Former names
- Consonance-HFW Acquisition Corp. (until Aug 11, 2021)
Other Biological Products, (No Diagnostic Substances) companies
- Amgen Inc AMGN
- Gilead Sciences, Inc. GILD
- Moderna, Inc. MRNA
- Argenx SE ARGX
- Revolution Medicines, Inc. RVMD
- Biogen Inc. BIIB
- BioNTech SE BNTX
- Exelixis, Inc. EXEL
All 182 Biological Products, (No Diagnostic Substances) companies
Key figures
Fiscal-year totals from the annual reports; switch to Annual for the full-year view. Balance sheet lines are as of each year end.
| Line | Q2 FY2026 Jun 30, 2026 |
Q1 FY2026 Mar 31, 2026 |
Q4 FY2025 Dec 31, 2025 |
Q3 FY2025 Sep 30, 2025 |
Q2 FY2025 Jun 30, 2025 |
|---|---|---|---|---|---|
| Revenue | $5.0M | $5.0M | $528,000 | $983,000 | $983,000 |
| Operating income | -$10.4M | -$10.5M | -$12.6M | -$10.9M | -$9.0M |
| Net income | $50.2M | -$127.5M | -$183.2M | -$71.6M | $39.7M |
| Diluted EPS | -$0.41 | -$11.65 | -$20,137.95 | -$8.36 | $2.55 |
| Operating cash flow | -$7.4M | -$12.5M | -$5.8M | -$9.0M | -$6.1M |
| Free cash flow | -$7.4M | -$12.6M | -$5.9M | -$9.1M | -$6.1M |
| Total assets | $115.6M | $120.7M | $98.7M | $94.0M | $102.7M |
| Total liabilities | $334.3M | $398.9M | $286.5M | $117.6M | $55.6M |
| Stockholders' equity | -$218.7M | -$278.1M | -$187.8M | -$23.5M | $47.1M |
| Cash and investments | $102.0M | $106.9M | $89.2M | $81.3M | $90.4M |
| Total debt | $6.3M | $6.8M | $6.6M | $7.1M | $7.5M |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 8-K |
Current report
Results of operations, Unregistered share sale
|
Oct 20, 2026 | Oct 20, 2026 |
| 8-K |
Current report
Other events
|
Oct 2, 2026 | Oct 2, 2026 |
| 10-Q | Quarterly report | Aug 6, 2026 | Jun 30, 2026 |
| 8-K |
Current report
Results of operations
|
Aug 6, 2026 | Aug 6, 2026 |
| 8-K |
Current report
Shareholder vote results
|
May 14, 2026 | May 13, 2026 |
| 10-Q | Quarterly report | May 6, 2026 | Mar 31, 2026 |
All 496 Surrozen, Inc./DE SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.